Relationship between clinical effectiveness and pharmacoeconomic cost in patients with diabetes mellitus

ETTARO, L. et al.: The economic burden of diabetes, Pharmaeconomics, 2004, 22, p. 149-16410.2165/00019053-200422030-00002Search in Google Scholar

DOLEŽAL, T. Farmakoekonomické aspekty liečby diabetu, Farmakoekoomika, 2006 3, 1, p.8-12Search in Google Scholar

GILMER, T. P. et al.: Predictors of health care costs in adults with diabetes, Diabetes care 2005, 28, p. 59-6410.2337/diacare.28.1.59Search in Google Scholar

FOLTÁN, V. et al.: Lieky, lieková politika, farmakoekonomika, 1 vydanie, Propact, 2003 186 sSearch in Google Scholar

EISENBERG, J. M.: Clinical economics: a guide to the economic analysis of clinical practices, JAMA, 1989, 262 (20), p.2879-288610.1001/jama.262.20.2879Search in Google Scholar

LILJAS, B.: How to calculate indirect costs in economic evaluations, Pharmacoeconomics, 1997, 13, (1), s. 1-710.2165/00019053-199813010-00001Search in Google Scholar

WORLD HEALTH ORGANIZATION. WHOQOL-BREF Introduction, Administration, Scoring and Generic Version of Assessment [online]. Geneva: The WHOQOL Group, 1997, p. 18 www.who.int/entity/mental_health/media/en/76.pdfSearch in Google Scholar

DŽUKA, J. et al. Psychological dimension of quality of life. Prešov: Prešov University, 2004. 519 p.Search in Google Scholar

ANDEL, M. et al.: A multinational, multicentre, observational, cross sectional survey assessing diabetes secondary care in Central and Eastern Europe (DEPAC SURVEY), Diabetic Medicine 2008, 25 (10), p. 25-3110.1111/j.1464-5491.2008.02570.xSearch in Google Scholar

TARRIDE JE - HOPKINS R - BLACKHOUSE G. et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics. 2010 Apr 1; 28(4), p. 255-77.10.2165/11531590-000000000-00000Search in Google Scholar

PALMER, A. J. et al.: The CORE diabetes model: Projecting long term clinical outcomes, costs and cost effectiveness of interventions in diabetes mellitus (types 1 and types 2) to support clinical and reimbursement decision-making, Curr Med Res Opin 2004, 20 (Suppl1):S5-S2610.1185/030079904X1980Search in Google Scholar

UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 1998, 352, p. 837-853.10.1016/S0140-6736(98)07019-6Search in Google Scholar

DRUMMOND M. F. - O BRIEN B. - STODDART G. L, - TORRANCE G. W.: Methods for the economic evaluation of health care programmes, Oxford University press, 2^nd edition, 2000, 305 p.Search in Google Scholar

MASSI-BENEDETTI, M.: The Cost of Diabetes Type II in Europe. The CODE-2 Study. Diabetologia 2002, 45; S1-S4.10.1007/s00125-002-0860-3Search in Google Scholar

ILAVSKA, A. - GLATZ, P. - HLOSKA, A. - FILKO, M. Economic evaluation of type 2 diabetes, impact of pricing and reimbursement reforms. In: Value in Health 2010. 13, 3, p. A66.10.1016/S1098-3015(10)72311-1Search in Google Scholar

KAMENSKÝ, G. Costs and benefits of preventive medication intervention in patients with high cardiovascular risk aged between 45 and 64 in Slovakia. Pharmacoeconomics and Drug Policy 2008, 4, 1, p. 11-17.Search in Google Scholar

SHABAN, A. et al.: The prevalence of depression and anxiety in adults with type 1 diabetes, Diabetic Medicine 2006, 23, p. 445-44810.1111/j.1464-5491.2006.01814.x16620276Search in Google Scholar

HRACHOVINOVÁ, T.: Depression and diabetes mellitus: psychosocial factors Available at http://journal.diabetes.org/clinicaldiabetes/v16n21998/PG91.htmlSearch in Google Scholar

HEISE, T. - PIEBER, T. R.: Towards peakless reproducible and long acting insulins. an assessment of the basal analogues based on isoglycemic clamp studies., Diabetes Obes Metab 2007, 9 (3), p. 290-29910.1111/j.1463-1326.2007.00756.x17645556Search in Google Scholar